argenx SE (ARGNF)
OTCMKTS · Delayed Price · Currency is USD
870.00
-2.27 (-0.26%)
At close: Nov 11, 2025
argenx SE Revenue
argenx SE had revenue of $1.15B in the quarter ending September 30, 2025, with 95.51% growth. This brings the company's revenue in the last twelve months to $3.69B, up 93.18% year-over-year. In the year 2024, argenx SE had annual revenue of $2.25B with 77.52% growth.
Revenue (ttm)
3.69B
Revenue Growth
+93.18%
P/S Ratio
14.54
Revenue / Employee
2.30M
Employees
1,599
Market Cap
53.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.25B | 983.45M | 77.52% |
| Dec 31, 2023 | 1.27B | 823.33M | 184.91% |
| Dec 31, 2022 | 445.27M | -94.15M | -17.45% |
| Dec 31, 2021 | 539.42M | 474.51M | 731.01% |
| Dec 31, 2020 | 64.91M | -29.11M | -30.96% |
| Dec 31, 2019 | 94.03M | 60.43M | 179.91% |
| Dec 31, 2018 | 33.59M | -15.91M | -32.14% |
| Dec 31, 2017 | 49.50M | 31.46M | 174.30% |
| Dec 31, 2016 | 18.05M | 7.24M | 66.96% |
| Dec 31, 2015 | 10.81M | 4.30M | 66.15% |
| Dec 31, 2014 | 6.51M | -719.25K | -9.95% |
| Dec 31, 2013 | 7.23M | 3.23M | 80.65% |
| Dec 31, 2012 | 4.00M | 11.07K | 0.28% |
| Dec 31, 2011 | 3.99M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 260.43M |
| Glass House Brands | 196.17M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Northwest Biotherapeutics | 937.00K |
argenx SE News
- 8 hours ago - argenx: TED Phase 3 Failure, Vyvgart Growth, And Why I'm Still A Hold - Seeking Alpha
- 13 hours ago - RBC Capital Raises Price Target for ARGX to $925, Maintains 'Outperform' | ARGX Stock News - GuruFocus
- 1 day ago - Wells Fargo Lowers Price Target for ARGX but Maintains Overweight Rating | ARGX Stock News - GuruFocus
- 1 day ago - Touchstone Sands Capital International Growth Equity Fund Q3 2025 Portfolio Update - Seeking Alpha
- 2 days ago - Argenx (ARGX) Ends Study of Efgartigimod for Thyroid Eye Disease - GuruFocus
- 2 days ago - Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Benzinga
- 2 days ago - Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Benzinga
- 2 days ago - Argenx Flops, As Viridian Celebrates, On Surprise Setback For Vyvgart Powerhouse - Investor's Business Daily